Clinical Trials on Diphtheria-Tetanus-acellular Pertussis Vaccines

Total 251 results

GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines

Australia
GlaxoSmithKline

Completed

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines

United States
Hillel Yaffe Medical Center

Recruiting

Immune Response followingTdap Vaccine in Pregnancy

Diphtheria-Tetanus-acellular Pertussis Vaccines

Israel
GlaxoSmithKline

Completed

Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | Aspergillosis, Allergic Bronchopulmonary

Colombia
GlaxoSmithKline

Completed

Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

Diphtheria-Tetanus-acellular Pertussis Vaccines

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women

Diphtheria-Tetanus-acellular Pertussis Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

Diphtheria-Tetanus-acellular Pertussis Vaccines

Russian Federation
GlaxoSmithKline

Completed

Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | Poliomyelitis

Korea, Republic of
GlaxoSmithKline

Completed

Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

Singapore
ABO Holdings, Inc.

Active, not recruiting

Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors

Tetanus, Diphtheria and Acellular Pertussis Vaccination

United States
GlaxoSmithKline

Completed

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Vietnam
GlaxoSmithKline

Terminated

Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia

Diphtheria-Tetanus-Acellular Pertussis

Colombia
Women and Infants Hospital of Rhode Island

Not yet recruiting

Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy (ITAPP)

Vaccine Exposure During Pregnancy | Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Non-birthing Partner Vaccination in Pregnancy
CanSino Biologics Inc.

Active, not recruiting

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Diphtheria, Tetanus and Acellular Pertussis

China
GlaxoSmithKline

Completed

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Evaluation of Boostrix™10 Years After Previous Booster Vaccination

Tetanus | Diphtheria | Acellular Pertussis

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)

Tetanus | Diphtheria | Acellular Pertussis

Spain, Netherlands, Belgium
GlaxoSmithKline

Terminated

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Tetanus | Diphtheria | Acellular Pertussis

Australia
GlaxoSmithKline

Completed

Post Market Surveillance for Infanrix™

Tetanus | Diphtheria | Acellular Pertussis

Korea, Republic of
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

Tetanus | Diphtheria | Acellular Pertussis

Mexico, Chile
GlaxoSmithKline

Completed

Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children

Tetanus | Diphtheria | Acellular Pertussis

Vietnam
GlaxoSmithKline

Completed

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Duration of Protection: GSK DTaP Vaccines

Tetanus | Diphtheria | Acellular Pertussis
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline

Completed

Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine

Diphteria, Tetanus and Pertussis
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
National Institute of Allergy and Infectious Diseases...

Completed

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

Pertussis | Tetanus | Diphtheria | Diphtheria Immunisation | Tetanus Immunisation | Clostridium Difficile Immunisation

Mali
GlaxoSmithKline

Completed

Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Sweden, Norway
GlaxoSmithKline

Completed

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.

Tetanus | Diphtheria | Acellular Pertussis

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline
Optum, Carolyn Martin and Ami Buikema

Completed

Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants

Tetanus | Diphtheria | Acellular Pertussis
GlaxoSmithKline

Completed

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

India
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

Tetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Tetanus | Diphtheria | Acellular Pertussis

Finland
GlaxoSmithKline

Completed

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

Tetanus | Diphtheria | Acellular Pertussis
GlaxoSmithKline

Completed

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

Tetanus | Diphtheria | Acellular Pertussis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish Children

Diphtheria, Tetanus and Pertussis

Spain
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Poliomyelitis Vaccine

South Africa

Clinical Trials on Diphtheria-Tetanus-acellular Pertussis Vaccines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations